Background
==========

Carcinomas classified as ovarian are the fourth most common female cancer, accounting for 225,000 (3.7%) of all new cases and 140,000 (4.2%) of all cancer deaths globally \[[@B1]\]. Known mutations in high penetrance genes are the best-defined risk factors, explaining \~10-15% of all epithelial ovarian carcinomas \[[@B2]-[@B6]\], while common variants in low penetrance genes may account for a smaller fraction (\~3%) of the polygenic component \[[@B7]-[@B9]\]. Non-genetic factors associated with the development of ovarian carcinoma include reduced risk with oral contraceptive use \[[@B10],[@B11]\], number of full-term pregnancies \[[@B12],[@B13]\], long-term breastfeeding \[[@B14]\] and tubal ligation or salpingectomy in *BRCA1/2* mutation carriers \[[@B12]\]. The independent contribution of modifiable environmental \[[@B15],[@B16]\] and lifestyle or behavioral \[[@B17]-[@B21]\] factors including diet is inconclusive, and only a few studies have confirmed non-genetic risk factor associations according to histologic type \[[@B14],[@B22]-[@B25]\].

Several studies examined the association between total alcohol consumption and ovarian carcinoma and reported inverse \[[@B17],[@B26],[@B27]\], null \[[@B28]-[@B31]\], or positive \[[@B32],[@B33]\] trends with the highest category of alcohol intake. Increased risk was also found among the mucinous histologic type \[[@B34],[@B35]\]. An earlier pooled analysis of prospective studies found no association between ≥30 g/d total alcohol intake compared to 0 g/d among 2,001 cases of ovarian carcinoma (RR, 1.12; 95% CI, 0.86-1.44), or for alcohol modeled continuously among 121 cases with mucinous histology (RR, 1.06; 95% CI, 0.84-1.34) \[[@B36]\]. A previous meta-analysis reported no overall association between alcohol consumption and ovarian carcinoma, but did find a 6% increased risk of mucinous ovarian carcinomas (95% CI, 1.01, 1.12, n=581) with each increase in intake of 10 g/day alcohol using continuous estimates obtained from authors of primary reports \[[@B37]\]. A more recent meta-analysis of 27 observational studies found no overall association of moderate or heavy drinking, but found an inverse trend with endometrioid ovarian carcinoma from three studies reporting associations by histology \[[@B38]\]. Two other reports summarized the epidemiologic evidence of the relation between alcohol and ovarian carcinoma descriptively \[[@B39]\] and as a systematic review \[[@B27]\]. Reviews or meta-analytic techniques that summarize categorical data from primary investigations comparing highest to lowest intakes have several limitations, including a loss of data when intermediate intake categories are excluded, which may introduce reporting bias, a problem termed "publication bias *in situ*" \[[@B40]\]. Additionally, primary studies differ in their adjustment for important confounders, in whether they distinguish invasive cancers from borderline tumors, which differ genetically, molecularly and clinically \[[@B41],[@B42]\], and in whether they reported associations separately by histologic type. These differences challenge the ability to synthesize published findings. To circumvent these limitations, we conducted a large pooled analysis of original data from 12 studies participating in the Ovarian Cancer Association Consortium (OCAC).

Methods
=======

Study subjects
--------------

Twelve studies of ovarian cancer that contributed data are described in Table [1](#T1){ref-type="table"}. All studies used population-based ascertainment methods for identifying eligible cases and controls and most studies matched cases to controls on age or age and region of residence. Eight studies were from the United States or Canada (CON \[[@B43]\], DOV \[[@B44]\], HAW \[[@B45]\], HOP \[[@B46]\], NCO \[[@B47],[@B48]\], NEC \[[@B49],[@B50]\], NJO \[[@B51],[@B52]\] and SON \[[@B53]\]), three were from Europe (GER \[[@B54]\], MAL \[[@B55]-[@B57]\] and POL \[[@B58]\]) and one was from Australia (AUS \[[@B59]\]). Informed consent was obtained from participating subjects in each of the individual studies, and local human research investigations committees approved each study.

###### 

Overview of OCAC studies

  **Study acronym**       **Study name**                                                                                **Controls, n**   **Cases, n**  **White non-Hispanic %**^**\***^   **Carcinoma cases with grade information %**†   **Recruitment year and location**   **Matching variables**‡                                                                    
  ----------------------- -------------------------------------------------------------------------------------------- ----------------- -------------- ---------------------------------- ----------------------------------------------- ----------------------------------- ------------------------- ----- ------ ------- ------------------------------------------- --------------------------------------------------------------------
  AUS \[[@B59]\]          AOCS (Australian Ovarian Cancer Study) and ACS (Australian Cancer Study -- Ovarian Cancer)         1,333            259       882                                537                                             39                                  106                       71    93.3   92.8    2002-2006; Australia                        State of residence and 5-year age groups
  CON \[[@B43]\]          CON (Connecticut Ovarian Cancer Study)                                                              526             103       339                                193                                             18                                  70                        33    91.7   85.4    1998-2003; Connecticut, USA                 3 age strata (35-49, 50-64 and 65-79 years)
  DOV \[[@B44]\]          DOVE (Diseases of the Ovary and their Evaluation)                                                  1,116            189       483                                269                                             20                                  81                        31    90.9   82.7    2002-2005 and 2006-2009; Washington, USA    5-year age groups, 1-year calendar intervals and two county strata
  GER \[[@B54]\]          GOCS (German Ovarian Cancer Study)                                                                  502              30       209                                107                                             24                                  23                        6     99.9   100     1993-1996; Germany                          Age and study region
  HAW \[[@B45]\]          HAWAII (Hawaii Ovarian Cancer Study)                                                               1,100             97       384                                176                                             42                                  68                        50    31.9   91.3    1993-2008; Hawaii, USA                      5-year age groups and race
  HOP \[[@B46]\]          HOPE (Hormones and Ovarian Cancer Prediction Study)                                                1,365             76       530                                289                                             27                                  71                        46    96.0   94.1    2003-2009; Pennsylvania, USA                5-year age groups and area code plus 3 number prefix
  MAL \[[@B55]-[@B57]\]   MALOVA (Malignant Ovarian Cancer Study)                                                             908             115       267                                157                                             30                                  41                        21    100    93.9    1994-1999; Denmark                          5-year age groups
  NCO \[[@B47],[@B48]\]   NCOCS (North Carolina Ovarian Cancer Study)                                                         979             212       777                                429                                             44                                  126                       82    80.9   100     1999-2008; North Carolina, USA              5-year age groups and race
  NEC \[[@B49],[@B50]\]   NECC (New England-based Case-Control Study)                                                        1,109            274       707                                386                                             47                                  152                       96    96.3   100     1992-1997 and 1998-2003; New England, USA   5-year age groups and region of residence
  NJO \[[@B51],[@B52]\]   NJOCS (New Jersey Ovarian Cancer Study)                                                             277              0        183                                104                                             7                                   30                        24    87.6   87.2    2002-2008; New Jersey, USA                  None
  POL \[[@B58]\]          POL (Polish Ovarian Cancer Control Study)                                                           601              18       236                                101                                             25                                  52                        13    100    66.3    2000-2003; Poland                           5-year age groups and study center
  SON \[[@B53]\]          SON (Southern Ontario Study of Reproduction, Diet and Health)                                       542              82       345                                200                                             38                                  65                        28    98.3   0       1989-1992; Southern Ontario                 3 age strata (35-49, 50-64 and 65-79 years)
  Totals                                                                                                                    10,358           1,455      5,342                              2,948                                           361                                 885                       501   87.7   84.86                                                

\* White non-Hispanic subjects as a percentage of all race-ethnicities enrolled in each study.

† Percentages reflect grade available for serous, mucinous and endometrioid carcinomas and for which we applied the algorithm to reduce histologic misclassification (see Methods).

‡ All studies except GER used frequency matching.

§ Includes the epithelial histologic types: serous, mucinous, endometrioid, clear cell, mixed epithelial, transitional cell, squamous cell, and undifferentiated.

Alcohol assessment and covariate data collection
------------------------------------------------

The unit of analysis for alcohol consumption was average daily grams of alcohol intake (g/d). Daily alcohol intake was estimated using validated food frequency questionnaires (FFQs) in AUS \[[@B60]\], DOV \[[@B61]\], HAW \[[@B62]\], MAL, NEC \[[@B63]\], NJO \[[@B51]\] and SON \[[@B53]\]. The exposure period was the year preceding recruitment (AUS, HAW, MAL, NEC, NJO and SON) or the time period approximately four years before the reference date (DOV). The remaining studies did not use FFQs but embedded questions regarding alcohol intake in risk factor questionnaires (CON \[[@B43]\], GER, HOP \[[@B34]\], NCO and POL). The exposure period for these studies was habitual regular drinking at the reference date (HOP) or the time period approximately five years before the reference date (CON, GER, NCO and POL). Daily alcohol intake for all studies was calculated by summing the product of the frequency of consumption of a specified serving of alcoholic beverage (beer, wine and liquor) by the alcohol content of that beverage using national estimates of alcohol content for that country. Total alcohol was estimated as the sum of alcohol intake across all alcoholic beverage types and submitted for pooled analysis. A subset of studies (AUS, CON, DOV, HAW, HOP and NEC) provided information for white and red wine separately.

Key clinical, demographic and questionnaire data on study subjects were merged into a common dataset and included case-control status, ethnicity/race, tumor behavior and histology, age at diagnosis (or comparable reference date for controls), history of prior cancers, current/former/never smoking status, menopausal status, oral contraceptive use, tubal ligation, endometriosis, hysterectomy, family history of breast or ovarian cancer in first-degree relatives, parity, age at last parturition, interview year, age at menarche, body mass index (BMI) and study site. Total energy intake was obtained from studies that collected dietary information using FFQs (AUS, DOV, HAW, NEC, NJO and SON). The data were checked for consistency and completeness and discrepancies were followed-up with individual study investigators.

We excluded from analyses subjects with non-epithelial ovarian tumors, prior histories of cancer other than non-melanoma skin cancer or subjects with missing information for total alcohol intake. Data were available from 5,342 cases of incident ovarian carcinoma, 1,455 women with incident ovarian borderline tumors and 10,358 controls (Table [1](#T1){ref-type="table"}).

Statistical analysis
--------------------

The studies were combined into a single dataset for analysis. Alcohol intake categories were derived in increments of one standard drink (g ethanol content) consumed daily: alcohol from any source (10 g); 12 oz beer (12.2 g), 4 oz wine (10.5 g) and 1 oz liquor (9.5 g). Primary analyses evaluated associations between alcohol intake and risk of ovarian carcinoma (excluding borderline tumors) using unconditional logistic regression to estimate odds ratios (OR) and 95% confidence intervals (CI). Trends in risk were evaluated by modeling the ordinal variable representing the category values of alcohol intake (e.g., 1, 2, 3) in the regression models with 1 degree-of-freedom \[[@B64]\]. Statistical heterogeneity in ORs across studies was evaluated using the likelihood ratio test comparing models with and without an interaction term between alcohol intake and study site. To describe further the degree of statistical heterogeneity, we estimated *I*^*2*^, the between-group variance \[[@B65]\], which describes the proportion of total variation in estimates of the ORs due to the heterogeneity between groups of studies. We estimated *I*^*2*^ to evaluate statistical heterogeneity between studies defined by their continent of origin. Groups of studies with statistically homogeneous ORs have an *I*^*2*^ value of zero.

All models were adjusted for the known or potential confounders footnoted in the tables. Risk models associated with total alcohol intake did not include other alcoholic beverage types. Risk models associated with beer, wine or liquor intake included all three beverage types and were thus adjusted for each other. Risk models associated with white or red wine intake included both types of wine as well as beer and liquor intake. To account for potential heterogeneity of summary risk estimates across studies, all models included interaction terms between every non-alcohol covariate and study site and are thus equivalent to fixed-effects meta-analyses, although the exclusion of these terms did not alter the risk estimates appreciably (data not shown). In addition, among a subset of studies, primary analyses were also adjusted for total energy intake, excluding subjects with extreme total energy values as previously described \[[@B66]\] and using the residual method \[[@B67]\], in order to evaluate the extent of confounding from this variable.

For the 12 studies combined, we simultaneously modeled the risk of each of five histologic types of ovarian carcinoma (high-grade serous, low-grade serous, mucinous, endometrioid and clear cell) and two of the four main types of borderline tumors with sufficient numbers for analysis (serous and mucinous) using polytomous logistic regression \[[@B68]\]. Risk models were adjusted for all covariates but excluded the interactions between non-alcohol covariates and study site to ease statistical computation. Statistical heterogeneity of the alcohol-ovarian tumor histology associations was tested separately for the carcinomas and the borderline tumors and was evaluated using the type 3 analysis of effects with degrees-of-freedom equal to the number of response levels minus one times the number of exposure levels minus one \[[@B68]\]. For these models, we incorporated considerations from the contemporary pathology literature to refine risk associations in the analyses of histologic type, as implemented previously \[[@B69]\]. Specifically, others have shown that an appreciable proportion of grade 3 mucinous ovarian carcinomas are, in fact, metastatic from the gastrointestinal tract \[[@B70]\], up to one-third of endometrioid ovarian carcinomas are high-grade serous ovarian carcinomas \[[@B71],[@B72]\] and approximately 3% of epithelial ovarian carcinomas are low-grade serous \[[@B71],[@B72]\]. We, therefore, re-assigned histologic type according to the expected distributions of histology combined with grade observed from large population-based series \[[@B71],[@B72]\] as follows. Endometrioid carcinomas were re-classified as high-grade serous carcinomas if their grade was ≥G3, mucinous carcinomas were assumed to be metastatic and excluded from analysis if ≥G3, and serous histology was re-classified as either low-grade serous carcinomas (G1) or high-grade serous carcinomas (≥G2).

Because of the reported association between smoking and ovarian carcinoma and, particularly for mucinous ovarian carcinoma and mucinous borderline tumors \[[@B22],[@B24],[@B25]\], statistical interaction was evaluated using the likelihood ratio test comparing models with and without an interaction term for the categorical forms of alcohol intake and smoking status (never, current and former). We also performed stratified analyses of alcohol intake across categories of smoking status. Potential modification of the alcohol-ovarian carcinoma association by other variables was examined using a similar approach.

Statistical tests were two-sided and implemented with SAS (SAS Institute, Cary, NC, Version 9.1). Funnel plots representing the study-specific and combined data estimates were derived from the logistic regression models as described above.

Results
=======

Characteristics of included studies and participants
----------------------------------------------------

Table [1](#T1){ref-type="table"} describes the characteristics of the 12 case-control studies. Eighty-eight percent of the cases were white non-Hispanic and \~85% of the carcinomas had information on tumor grade. The distribution of alcohol intake is shown in Additional file [1](#S1){ref-type="supplementary-material"}: Table S1, overall and for each study separately. Overall, average daily total alcohol intake ranged from approximately one-fifth of a standard drink at the 25^th^ percentile to 1-2 drinks at the 75^th^ percentile of the distributions. More women consumed wine than the other alcoholic beverages.

Generally, cases and controls were similar in their distributions across covariates (Additional file [1](#S1){ref-type="supplementary-material"}: Table S2**).** As expected, however, cases were more frequently postmenopausal than controls, were more likely to be nulliparous, and less likely than controls to have used oral contraceptive hormones for appreciable durations or to have had tubal ligation or a hysterectomy. The majority (\~75%) of subjects were recruited in the past decade. The distribution of covariates did not differ by much among controls who consumed beer, wine or liquor except, perhaps, that fewer wine consumers were current smokers and a greater proportion of beer drinkers were pre- or peri-menopausal.

Alcohol consumption and risk of ovarian carcinoma
-------------------------------------------------

In multivariable-adjusted pooled analyses, total alcohol intake from any source was not associated with risk of ovarian carcinoma (consumption of \>3 drinks per day compared to none: OR=0.92, 95% CI=0.76-1.10, P trend=0.27; Table [2](#T2){ref-type="table"}). Given the absence of a dose-response relationship, we modeled the variable dichotomously (none, any regular consumption) (Figure [1](#F1){ref-type="fig"}). Adjustment for known or suspected confounders beyond age and race (Figure [1A](#F1){ref-type="fig"}**)** tended to attenuate risk associations (Figure [1B](#F1){ref-type="fig"}) indicating the importance of accounting for these variables in the analysis. Further adjustment for total energy had little effect (data not shown).

###### 

Association between consumers of alcoholic beverages and ovarian carcinoma, OCAC studies

  **Intake/d**            **Ca/Co**       **OR (95% CI)**
  ------------------- ------------------ ------------------
  **Total alcohol**    **5,342/10,358**           
   None                  2,269/4,296         1.0 (Ref)
   Up to 1 drink \*      2,074/3,928      0.94 (0.85-1.03)
   1-2 drinks             560/1,112       0.97 (0.85-1.11)
   2-3 drinks              192/400        0.91 (0.74-1.11)
   \>3 drinks              247/622        0.92 (0.76-1.10)
  P trend                                       0.27
  **Beer**†                                       
   None                  4,016/7,472         1.0 (Ref)
   Up to 12 oz           1,179/2,570      0.92 (0.83-1.02)
   \>12 oz                 147/315        1.09 (0.86-1.37)
  P trend                                       0.43
  **Wine**†                                       
   None                  2,821/5,307         1.0 (Ref)
   Up to 4 oz            2,057/3,984      0.94 (0.85-1.04)
   4-8 oz                  261/522        1.00 (0.83-1.20)
   \>8 oz                  203/545        0.83 (0.68-1.01)
  P trend                                       0.08
  **White wine**‡                                 
   None                  2,110/4,114         1.0 (Ref)
   Up to 4 oz            1,053/2,032      0.93 (0.82-1.06)
   \>4 oz                  162/406        0.97 (0.77-1.21)
  P trend                                       0.26
  **Red wine**‡                                   
   None                  2,330/4,548         1.0 (Ref)
   Up to 4 oz             866/1,665       0.92 (0.81-1.05)
   \>4 oz                  129/336        0.90 (0.71-1.15)
  P trend                                       0.11
  **Liquor**†                                     
   None                  3,599/6,865         1.0 (Ref)
   Up to 1 oz            1,535/3,061      0.97 (0.88-1.08)
   \>1 oz                  208/431        1.03 (0.85-1.26)
   P trend                                      0.82

Adjusted for age (\<40; 40-49; 50-59; 60-69; 70+ years), smoking status (never, former, current), site (AUS, CON, DOV, GER, HAW, HOP, MAL, NCO, NEC, NJO, POL, SON), race/ethnicity (white nonHispanic; white Hispanic; black non Hispanic; Asian; other or unknown); menopausal status (pre/peri-menopausal; postmenopausal, unknown or missing), oral contraceptive use (\<6mo, 6-22 mo, 23+ mo, unknown or missing), tubal ligation (yes; no; unknown or missing), endometriosis (yes; no; unknown or missing), hysterectomy (yes; no; unknown or missing), family history of breast or ovarian cancer in first-degree relatives (no; yes; unknown; no daughters or sisters), parity/age at last birth (nulliparous; 1-2 births/age ≤25 yrs at last pregnancy; 3+ births/age ≤25 yrs at last pregnancy; 1-2 births/age \>25 years at last pregnancy; 3+ births/age \>25 years at last pregnancy; yes if ever pregnant but unknown or missing age at last pregnancy age; no or unknown if ever pregnant and missing age at last pregnancy, interview year (1990-1994; 1995-1999; 2000-2004; 2005-2009; missing), age at menarche (8-10 yrs; 11 yrs; 12 yrs; 13 yrs; 14-21 yrs; \<8 or ≥ 22 yrs), body mass index (continuous) and education (less than high school, high school, some college, completed college or university, completed graduate or professional degree, missing). Models include interaction terms between site and each covariate except alcohol.

\* 1 drink = 10 grams ethanol.

† Models are also simultaneously adjusted for consumption of beer, wine and liquor intake.

‡ White/red wine information available from AUS, CON, DOV, HAW, HOP and NEC only. Models are simultaneously adjusted for beer and liquor intake.

![**Funnel plot of study-specific and summary OR and 95% CI for the association between alcohol intake (none, any) and ovarian carcinoma in 12 OCAC studies.**Squares indicate study-specific OR; the size of the squares is proportional to study-specific sample size; the width of lines indicates the study-specific 95% CI; diamonds indicate summary OR; the width of the diamonds indicates summary 95% CI. Refer to Table [1](#T1){ref-type="table"} for study nomenclature. [1A](#F1){ref-type="fig"}**:**Age and race adjusted OR and 95% CI. Statistical heterogeneity in ORs across studies, P value \< 0.0001 (see Statistical analysis). 1**B:** Multivariable-adjusted OR and 95% CI. Adjusted for variables in footnote of Table [2](#T2){ref-type="table"}. Statistical heterogeneity in ORs across studies, P value = 0.03.](1471-2407-13-28-1){#F1}

Alcoholic beverage type and risk of ovarian carcinoma
-----------------------------------------------------

All studies provided information on type of alcoholic beverage consumed (beer, wine and liquor). Compared to women who reported no wine intake, we observed a statistically non-significant decreased risk associated with consumption of more than 8 oz/d of wine after adjusting for consumption of other types of alcoholic beverage intake (OR=0.83, 95% CI=0.68-1.01, P trend=0.08; Table [2](#T2){ref-type="table"}). Associations did not differ by much when we restricted the analyses to those individuals who consumed only one type of alcoholic beverage (data not shown). Among a subset of studies with information on white or red wine consumed, risk associations were not statistically significant.

Alcohol and ovarian tumor histologic types
------------------------------------------

More than 3 average drinks/d of alcohol intake from any source was associated with a lower risk of endometrioid ovarian carcinoma (OR=0.49, 95% CI=0.27-0.91), although this was no longer evident when the two highest intake categories were combined (\>2 drinks/d: OR=0.85, 95% CI=0.58-1.26; P trend=0.45; Table [3](#T3){ref-type="table"}). We observed a statistically significant inverse trend between consumption of wine and clear cell ovarian carcinomas with a decreased risk at higher intakes only (\>8 oz/d: OR=0.43, 95% CI=0.22-0.83; P trend=0.02). This association, however, was based on 10 cases and the heterogeneity between histologic types was not statistically significant (P heterogeneity=0.09). Following combining the two highest intake categories, the association remained suggestive (\>4 oz/d: OR=0.70, 95% CI=0.47-1.03, P trend=0.05; Table [3](#T3){ref-type="table"}). A statistically non-significant increased risk was also seen between total alcohol intake over 3 average drinks/d and mucinous borderline tumors (OR=1.40, 95% CI=0.99-1.20; P trend=0.22, Table [4](#T4){ref-type="table"}, data shown for total alcohol and wine only) but disappeared following combining the two highest intake categories (\>4 oz/d: OR=1.22, 95% CI=0.90-1.66, P trend=0.42; Table [4](#T4){ref-type="table"}). Application of the pathology-based algorithm tended to shift estimates and 95% CIs farther from the null, although there was no appreciable difference in significance of estimates when the algorithm was not implemented (Additional file [1](#S1){ref-type="supplementary-material"}: Table S3).

###### 

Association between total alcohol and wine intake and histological types\* of ovarian carcinoma, OCAC studies

  **Intake/d**           **Controls N=10,358**   **High-Grade Serous N=2,580**   **Mucinous N=245**   **Endometrioid N=506**   **Clear Cell N=501**   **Low-Grade Serous N=198**                                                                      
  --------------------- ----------------------- ------------------------------- -------------------- ------------------------ ---------------------- ---------------------------- ------------------ ----- ------------------ ---- ------------------ ------
  **Total alcohol** ‡                                                                                                                                                                                                                                    
   None                          4,296                       1,060                   1.0 (Ref)                  98                  1.0 (Ref)                    214                  1.0 (Ref)       223      1.0 (Ref)       61      1.0 (Ref)         
   Up to 1 drink                 3,928                       1,029                0.95 (0.84-1.07)              97               1.08 (0.76-1.52)                207               0.97 (0.76-1.23)   188   0.84 (0.66-1.07)   90   0.95 (0.65-1.38)     
   1-2 drinks                    1,112                        282                 0.97 (0.83-1.15)              26               1.08 (0.66-1.75)                 50               0.96 (0.68-1.36)   53    0.97 (0.69-1.37)   29   1.28 (0.78-2.11)     
   2-3 drinks                     400                         79                  0.78 (0.60-1.02)              11               1.36 (0.69-2.67)                 23               1.36 (0.85-2.19)   17    0.96 (0.56-1.63)   8    0.98 (0.45-2.13)     
   \>3 drinks                     622                         130                 0.96 (0.77-1.20)              13               0.98 (0.52-1.82)                 12               0.49 (0.27-0.91)   20    0.82 (0.50-1.34)   10   1.12 (0.55-2.29)     
  P trend                                                                               0.31                                           0.71                                              0.25                     0.50                    0.54         0.67
   \>2 drinks§                   1,022                        209                 0.88 (0.74-1.06)              24               1.12 (0.69-1.83)                 35               0.85 (0.58-1.26)   37    0.88 (0.60-1.30)   18   1.05 (0.59-1.86)     
  P trend §                                                                             0.24                                           0.62                                              0.45                     0.52                    0.53         0.71
  **Wine**                                                                                                                                                                                                                                               
   None                          5,307                       1,316                   1.0 (Ref)                 128                  1.0 (Ref)                    263                  1.0 (Ref)       272      1.0 (Ref)       81      1.0 (Ref)         
   Up to 4 oz                    3,984                       1,022                0.93 (0.83-1.04)             103               1.12 (0.81-1.54)                206               0.96 (0.77-1.21)   195   0.87 (0.69-1.09)   91   0.94 (0.66-1.34)     
   4-8 oz                         522                         129                 0.93 (0.75-1.16)              10               1.03 (0.52-2.04)                 22               0.98 (0.61-1.58)   24    0.95 (0.60-1.50)   13   1.33 (0.70-2.50)     
   \>8 oz                         545                         113                 0.86 (0.68-1.09)              4                0.39 (0.14-1.09)                 15               0.68 (0.39-1.20)   10    0.43 (0.22-0.83)   13   1.35 (0.71-2.56)     
  P trend                                                                               0.13                                           0.32                                              0.29                     0.02                    0.34         0.09
   \>4 oz §                      1,067                        242                 0.89 (0.75-1.06)              14               0.70 (0.39-1.27)                 37               0.84 (0.57-1.23)   34    0.70 (0.47-1.03)   26   1.34 (0.81-2.20)     
  P trend §                                                                             0.13                                           0.61                                              0.41                     0.05                    0.44         0.25

Adjusted for age (\<40; 40-49; 50-59; 60-69; 70+ years), smoking status (never, former, current), site (AUS, CON, DOV, GER, HAW, HOP, MAL, NCO, NEC, NJO, POL, SON), race/ethnicity (white nonHispanic; white Hispanic; black non Hispanic; Asian; other or unknown); menopausal status (pre/peri-menopausal; postmenopausal, unknown or missing), oral contraceptive use (\<6mo, 6-22 mo, 23+ mo, unknown or missing), tubal ligation (yes; no; unknown or missing), endometriosis (yes; no; unknown or missing), hysterectomy (yes; no; unknown or missing), family history of breast or ovarian cancer in first-degree relatives (no; yes; unknown; no daughters or sisters), parity/age at last birth (nulliparous; 1-2 births/age ≤25 yrs at last pregnancy; 3+ births/age ≤25 yrs at last pregnancy; 1-2 births/age \>25 years at last pregnancy; 3+ births/age \>25 years at last pregnancy; yes if ever pregnant but unknown or missing age at last pregnancy age; no or unknown if ever pregnant and missing age at last pregnancy, interview year (1990-1994; 1995-1999; 2000-2004; 2005-2009; missing), age at menarche (8-10 yrs; 11 yrs; 12 yrs; 13 yrs; 14-21 yrs; \<8 or ≥ 22 yrs), body mass index (continuous) and education (less than high school, high school, some college, completed college or university, completed graduate or professional degree, missing).

\* Cases restricted to samples with information on grade for serous, mucinous and endometrioid histologic types, and for whom we applied the algorithm to reduce histologic misclassification (see Methods).

† *P* for tumor heterogeneity derived from testing the trend variable for alcohol or wine intake in polytomous regression models with 5 df (see Statistical analysis).

‡ 1 drink = 10 grams ethanol.

§ Risk estimates and P trend values are from models that collapse the two highest intake categories.

Models are also simultaneously adjusted for consumption of beer and liquor intake.

###### 

Association between total alcohol and wine intake and ovarian borderline tumors, OCAC studies

  **Intake/d**           **Controls N=10,358**    **Serous borderline N=818**   **Mucinous borderline N=561**                              
  ---------------------- ----------------------- ----------------------------- ------------------------------- -------- ------------------ ---------------
  **Total alcohol** \*                                      **Ca**                     **OR (95% CI)**          **Ca**   **OR (95% CI)**   ***P*value†**
   None                  4,296                                297                         1.0 (Ref)              181        1.0 (Ref)       
   Up to 1 drink         3,928                                349                     0.87 (0.72-1.05)           245     0.95 (0.76-1.20)   
   1-2 drinks            1,112                                86                      0.91 (0.69-1.20)            59     0.86 (0.62-1.20)   
   2-3 drinks            400                                  32                      1.04 (0.69-1.56)            23     0.94 (0.58-1.51)   
   \>3 drinks            622                                  54                      1.19 (0.86-1.66)            53     1.40 (0.99-1.20)   
  P trend                                                                                   0.45                               0.22        0.39
   \>2 drinks §          1,022                                86                      1.13 (0.86-1.49)            76     1.22 (0.90-1.66)   
  P trend §                                                                                 0.63                               0.42        0.67
  **Wine**                                                                                                                                  
   None                  5,307                                405                         1.0 (Ref)              263        1.0 (Ref)       
   Up to 4 oz            3,984                                336                     0.89 (0.74-1.06)           236     0.89 (0.72-1.10)   
   4-8 oz                522                                  38                      0.99 (0.68-1.43)            26     0.88 (0.57-1.36)   
   \>8 oz                545                                  39                      0.99 (0.69-1.44)            36     1.03 (0.69-1.52)   
  P trend                                                                                   0.66                               0.72        0.87
   \>4 oz §              1,067                                77                      0.99 (0.75-1.31)            62     0.96 (0.70-1.31)   
  P trend §                                                                                 0.52                               0.52        0.69

Adjusted for age (\<40; 40-49; 50-59; 60-69; 70+ years), smoking status (never, former, current), site (AUS, CON, DOV, GER, HAW, HOP, MAL, NCO, NEC, NJO, POL, SON), race/ethnicity (white nonHispanic; white Hispanic; black non Hispanic; Asian; other or unknown); menopausal status (pre/peri-menopausal; postmenopausal, unknown or missing), oral contraceptive use (\<6mo, 6-22 mo, 23+ mo, unknown or missing), tubal ligation (yes; no; unknown or missing), endometriosis (yes; no; unknown or missing), hysterectomy (yes; no; unknown or missing), family history of breast or ovarian cancer in first-degree relatives (no; yes; unknown; no daughters or sisters), parity/age at last birth (nulliparous; 1-2 births/age ≤25 yrs at last pregnancy; 3+ births/age ≤25 yrs at last pregnancy; 1-2 births/age \>25 years at last pregnancy; 3+ births/age \>25 years at last pregnancy; yes if ever pregnant but unknown or missing age at last pregnancy age; no or unknown if ever pregnant and missing age at last pregnancy, interview year (1990-1994; 1995-1999; 2000-2004; 2005-2009; missing), age at menarche (8-10 yrs; 11 yrs; 12 yrs; 13 yrs; 14-21 yrs; \<8 or ≥ 22 yrs), body mass index (continuous) and education (less than high school, high school, some college, completed college or university, completed graduate or professional degree, missing). Wine consumption was additionally adjusted for other alcoholic beverage types. Models include interaction terms between site and each covariate except alcohol.

\* 1 drink = 10 grams ethanol.

† *P*for tumor heterogeneity derived from testing the trend variable for alcohol or wine intake in polytomous regression models with 2 df (see Statistical analysis).

§ Risk estimates and P trend values are from models that collapse the two highest intake categories.

Models are also simultaneously adjusted for consumption of beer and liquor intake.

Potential sources of effect modification
----------------------------------------

The association between total alcohol intake (none, any regular consumption) and risk of ovarian carcinoma varied somewhat across studies following multivariable adjustment (Figure [1B](#F1){ref-type="fig"}**,** P interaction=0.03); the source of heterogeneity was within the three European studies when evaluated by continent of study origin (within-group heterogeneity: Europe, *I*^*2*^=75%; North America, *I*^*2*^=0%). The association between wine intake (none, any regular consumption) and risk of ovarian carcinoma also varied across studies following multivariable adjustment (P interaction=0.01) and significant heterogeneity was again observed within the European studies (*I*^*2*^=81%). Within North American studies, the estimates for wine intake were statistically homogeneous for ovarian carcinoma overall (OR, 0.99; 95% CI, 0.89-1.10; *I*^*2*^=0%). We evaluated whether the decreased risk observed between wine intake and clear cell carcinomas (Table [3](#T3){ref-type="table"}) was influenced by the variability within European studies by excluding the three European studies. The association between consumption of \>8 oz/d wine and clear cell ovarian carcinomas remained significant (OR=0.48, 95% CI=0.25-0.95; P trend=0.03; 10 cases). Alcohol, in general, has been reported to reduce cellular proliferation by influencing the insulin and insulin-like growth factor (IGF) pathways \[[@B73],[@B74]\], and these pathways have been implicated in the early development and prognosis of clear cell carcinoma types \[[@B75]-[@B78]\]. Because obesity is associated with impaired insulin sensitivity \[[@B74]\], we tested the trend association of alcohol or wine intake with histologic types stratified by BMI (\<30 vs ≥30 kg/m^2^). There was no clear effect modification by BMI among any of the histologic types for total alcohol intake (data not shown), and suggestive decreased risks for wine intake at lower BMI for both clear cell carcinomas (BMI \<30 kg/m^2^: OR=0.83, 95% CI=0.69-1.00; n=382 cases vs BMI ≥30 kg/m^2^: OR=0.79, 95% CI=0.53-1.18; n=119 cases) and high-grade serous carcinomas (BMI \<30 kg/m^2^: OR=0.90, 95% CI=0.83-0.98; n=2,052 cases vs BMI ≥30 kg/m^2^: OR=1.17, 95% CI=0.96-1.42; n=528 cases). Smoking status did not significantly modify the association between ovarian carcinoma and total alcohol intake (P interaction=0.11) or wine intake (P interaction=0.97) (Additional file [1](#S1){ref-type="supplementary-material"}: Table S4) or between mucinous borderline tumors and total alcohol intake (data not shown). None of the other covariates statistically modified the alcohol- or wine-ovarian carcinoma association including race/ethnicity (P interactions ≥ 0.22) (data not shown).

Discussion
==========

While current guidelines for cancer prevention restrict alcohol drinking for women to no more than 1 drink per day \[[@B79]\], we found no evidence that recent moderate alcohol drinking increased overall ovarian carcinoma risk. Although there was some indication of effect modification by cell type, the statistical evidence was weak. This is the largest study to date to perform this evaluation quantitatively across the five types of ovarian carcinomas and the two groups of borderline ovarian tumors using individual-level data on alcohol intake.

Various oncogenic mechanisms of alcohol are well documented \[[@B80]\]. Although the evidence is convincing that alcohol is a risk factor for cancers of the breast and several cancers of the gastrointestinal tract \[[@B81]\], it has been equivocal for ovarian cancer \[[@B17],[@B26]-[@B33]\]. Overall, our investigation adds to the evidence that recent moderate alcohol consumption is not significantly associated with ovarian carcinoma. A number of design and analytic factors can lead to disparate findings across studies. For example, heterogeneity of risk estimates were observed in European studies, a finding also reported by others \[[@B38]\]. The type and range of alcohol intake varies considerably across European countries and should be interpreted carefully when data are pooled or evaluated meta-analytically across continents.

Previous studies reported decreased risk from wine intake \[[@B26],[@B27],[@B31],[@B82]\], although most associations were not statistically significant. The most widely reported constituents in wine are the polyphenols, including resveratrol, which derive mainly from the aerial tissues (grape skin) because their biosynthesis is stimulated by light \[[@B83]\]. Numerous anticarcinogenic properties of the polyphenols have been proposed \[[@B84]\]. A potentially interesting finding in the current study is the association between higher recent intakes of wine with decreased risk of clear cell ovarian carcinoma. The association persisted following exclusion of the European studies. A decreased risk from wine, but not beer or liquor, intake was also found among women in a pooled analysis of 12 prospective studies of renal cell carcinoma \[[@B85]\]. Clear cell ovarian carcinomas share similar features with clear cell renal cell carcinomas \[[@B86]-[@B88]\] and it has been suggested that moderate alcohol intake may improve insulin sensitivity and regulate related pathways \[[@B73],[@B74]\] that are implicated in the etiology of these carcinomas \[[@B75]-[@B78]\]. We observed suggestive decreased risks of wine intake among non-obese women for clear cell and high-grade serous ovarian carcinomas; however, we cannot exclude the possibility that these findings are due to chance.

Several key non-genetic risk factors for ovarian cancer were reported in the early 1990s, when studies established decreased risks associated with oral contraceptive use \[[@B10],[@B11]\], parity \[[@B12],[@B13]\] and breast-feeding \[[@B12]\]. Using our consortium data, we recently reported that endometriosis was associated with increased risk of endometrioid and clear cell ovarian carcinomas \[[@B23]\]. However, few modifiable risk factors for ovarian cancers have been found. Perhaps the only lifestyle factor that is most consistently associated with modified risk of ovarian cancers is smoking, which is associated with an increased risk of both mucinous ovarian carcinoma and mucinous borderline tumors \[[@B24],[@B25]\]. This emphasizes the importance of, and the need for more, pooled analyses of individual-level data that are harmonized carefully across different studies through collaborations within consortia, such as OCAC. Clearly, the research community struggles to understand the causes of the majority of these elusive and deadly cancers.

The strengths of this investigation include the analysis of individual-level data from a large sample as well as evaluation of higher levels of intakes (\>3 drinks/d) and the standardized method of alcohol analysis, which allowed us to quantify risk associations based on average daily grams of alcohol intake. Although we attempted to reduce potential misclassification of histologic type by applying a pathology-based algorithm, the associations were not appreciably different if the algorithm was not implemented, unlike previous analyses for other exposures where implementation of the algorithm appeared to refine those associations \[[@B69]\]. The large sample of histologic types permitted evaluation of a wider range of alcohol intake, particularly total alcohol and wine intake. While a potential limitation of all case-control studies is recall and selection bias, our pooled estimates are in agreement with other reports \[[@B36],[@B38]\]. Furthermore, although our findings relating moderate alcohol intake near the time of diagnosis indicated no association with ovarian carcinoma, it is possible that alcohol intake at other points in the life cycle may influence risk, given the long latency period estimated for these cancers \[[@B89]\].

Conclusions
===========

In conclusion, the results of this investigation do not support an association between recent moderate total alcohol intake and ovarian carcinoma overall. The findings do not strongly support variation in risk associated with specific histologic types. Understanding the modifiable causes of these deadly cancers through rigorous consortium analyses remains a priority for the research community.
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